Other senolytics include navitoclax (ABT-263), an inhibitor that targets anti-apoptotic members of the BCL-2 family, particularly BCL-2, BCL-W that restores the apoptosis of senescent cells, though its clinical use is limited by dose-dependent thrombocytopenia [233]. This evidence concerns the gene BCL2 and Thrombocytopenia.